In prostate cancer, androgen receptor (AR) has a central role in promoting the progression of prostate cancer and the inhibition of AR signaling by using androgen deprivation therapy (ADT) that represents the first treatment for castration-sensitive prostate cancer [3]. Here, AR is linked to prostate carcinoma.